MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study
(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial ...
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...